A new asset-backed securities (ABS) issue from Medfin Australia (Medfin), a subsidiary of National Australia Bank (NAB) that originates auto and equipment loans to the healthcare industry, has priced. Seven of the eight classes of notes that make up the deal, which was upsized to A$400 million (US$414 million) from an indicative volume of A$300 million, were given expected ratings by Fitch Ratings (Fitch) on September 25.